Q2 2019 Earnings Estimate for Amedisys Inc Issued By Oppenheimer (AMED)

Amedisys Inc (NASDAQ:AMED) – Research analysts at Oppenheimer lowered their Q2 2019 earnings estimates for shares of Amedisys in a report released on Tuesday, April 30th, according to Zacks Investment Research. Oppenheimer analyst M. Wiederhorn now anticipates that the health services provider will post earnings per share of $1.00 for the quarter, down from their previous forecast of $1.05. Oppenheimer also issued estimates for Amedisys’ FY2019 earnings at $4.09 EPS, Q3 2020 earnings at $1.09 EPS, Q4 2020 earnings at $1.18 EPS and FY2020 earnings at $4.47 EPS.

Amedisys (NASDAQ:AMED) last released its quarterly earnings data on Tuesday, April 30th. The health services provider reported $1.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.89 by $0.22. The business had revenue of $467.34 million for the quarter, compared to the consensus estimate of $460.83 million. Amedisys had a net margin of 7.14% and a return on equity of 28.25%. The company’s revenue was up 17.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.79 earnings per share.

A number of other equities research analysts also recently issued reports on AMED. BidaskClub downgraded shares of Amedisys from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 28th. Barclays increased their price target on shares of Amedisys from $115.00 to $120.00 and gave the stock an “equal weight” rating in a report on Thursday, March 21st. Zacks Investment Research downgraded shares of Amedisys from a “buy” rating to a “hold” rating in a report on Monday, January 21st. Raymond James raised shares of Amedisys from a “market perform” rating to an “outperform” rating and set a $140.00 price target on the stock in a report on Thursday, May 2nd. Finally, Craig Hallum lowered their price target on shares of Amedisys from $132.00 to $124.00 and set a “hold” rating on the stock in a report on Friday, March 1st. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, nine have issued a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $125.90.

NASDAQ AMED traded down $3.89 during trading on Thursday, hitting $108.34. 456,200 shares of the company’s stock traded hands, compared to its average volume of 469,627. The company has a market cap of $3.55 billion, a PE ratio of 29.85, a price-to-earnings-growth ratio of 1.38 and a beta of 1.33. Amedisys has a 12-month low of $71.74 and a 12-month high of $140.91. The company has a quick ratio of 0.91, a current ratio of 0.91 and a debt-to-equity ratio of 0.69.

Several large investors have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its stake in shares of Amedisys by 0.6% during the fourth quarter. BlackRock Inc. now owns 5,020,723 shares of the health services provider’s stock valued at $587,979,000 after purchasing an additional 28,382 shares during the period. Vanguard Group Inc. boosted its stake in shares of Amedisys by 14.3% during the third quarter. Vanguard Group Inc. now owns 3,326,180 shares of the health services provider’s stock valued at $415,640,000 after purchasing an additional 415,060 shares during the period. Vanguard Group Inc boosted its stake in shares of Amedisys by 14.3% during the third quarter. Vanguard Group Inc now owns 3,326,180 shares of the health services provider’s stock valued at $415,640,000 after purchasing an additional 415,060 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Amedisys by 14.6% during the third quarter. JPMorgan Chase & Co. now owns 934,137 shares of the health services provider’s stock valued at $116,731,000 after purchasing an additional 118,936 shares during the period. Finally, Acadian Asset Management LLC boosted its stake in shares of Amedisys by 31.6% during the fourth quarter. Acadian Asset Management LLC now owns 802,138 shares of the health services provider’s stock valued at $93,940,000 after purchasing an additional 192,552 shares during the period. 91.71% of the stock is owned by hedge funds and other institutional investors.

In related news, insider David B. Pearce sold 4,370 shares of the company’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $120.01, for a total value of $524,443.70. Following the transaction, the insider now directly owns 13,129 shares in the company, valued at $1,575,611.29. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jeffrey A. Rideout sold 1,411 shares of the stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $121.58, for a total transaction of $171,549.38. Following the transaction, the director now owns 4,557 shares in the company, valued at $554,040.06. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 18,281 shares of company stock worth $2,160,243. 2.90% of the stock is owned by company insiders.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Featured Story: The benefits and drawbacks of dollar cost averaging

Get a free copy of the Zacks research report on Amedisys (AMED)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.